Replies to post #172121 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

anavex pluas will no longer be discussed because a2-73 doesnt need DPZ to be effective..anavex is out protecting itself and concept as a the ultimate adjuvant..bu creating homeostasis a2-73 will allow additional treatments to be more effective, by allowing the use of more sometimes and sometimes less depending upon the indications..asn as a2-73 is only agaonizing teh bodys natural ability to create balance..negative interactions should be a minimum..
but i would imagine that you don't use a2-73 with any other drugs that agaonize or antagonize the s1r..
now if you had a drug that was agonixing the s2r..and you put it with the drug agaonzing the s1r..i have no idea what that would do..but it sounds good to me..Agonaize ME!

do they have lessons on how to speak Down Under?

[OFP]

All the data presented so far says DZP makes little difference to the effectiveness of A2-73.

Which you would not expect if 2-73 has any clinical action and they both have orthosteric binding.

A2-73 has allosteric binding

There is zero evidence for this.

i.e. not just to S1R and thus the two drugs likely have very different MOA

There is zero evidence for this.